Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Baclofen and midazolam alter c-fos induction by peripheral noxious or innocuous stimulation in the spinal cord of normal and monoarthritic rats
Publication

Publications

Baclofen and midazolam alter c-fos induction by peripheral noxious or innocuous stimulation in the spinal cord of normal and monoarthritic rats

Title
Baclofen and midazolam alter c-fos induction by peripheral noxious or innocuous stimulation in the spinal cord of normal and monoarthritic rats
Type
Another Publication in an International Scientific Journal
Year
1999
Authors
Castro, AR
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Bowery, N
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Castro-Lopes J.M.
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Journal
Title: NeuropharmacologyImported from Authenticus Search for Journal Publications
Vol. 38
Pages: 1775-1788
ISSN: 0028-3908
Publisher: Elsevier
Other information
Authenticus ID: P-001-315
Abstract (EN): In order to further clarify the role of gamma-aminobutyric acid (GABA) receptors in spinal sensory processing we have studied the effects of baclofen, a GABA(B) agonist, and midazolam, a benzodiazepine agonist, on the activation of Spinal neurones by peripheral innocuous or noxious stimulation, in normal or monoarthritic rats, as signalled by the induction of the proto-oncogene c-fos. Baclofen (10 mg/kg, i.v.) caused a significant reduction in the number of Fos-positive neurones following noxious stimulation of both normal and monoarthritic animals, which was prevented by the GABA(B) antagonist CGP 35348 (200 mg/kg, i.v.). The latter caused an increase of c-fos expression in normal animals subject to noxious stimulation, suggesting an endogenous tonic activation of GABA(B) receptors. This effect was not observed in monoarthritic animals. Baclofen also reduced the number of Fos-positive neurones in monoarthritic animals subject to innocuous stimulation. Midazolam (5 mg/kg, i.v.) had no effect in normal animals, but caused an increase in c-fos expression induced by noxious stimulation in monoarthritic animals. Flumazenil (1 mg/kg, i.v.), a benzodiazepine antagonist, prevented the effect of midazolam, and if given alone evoked a decrease in Fos-positive neurones. It can be concluded that although GABA(B) receptors modulate sensory input at the spinal level, high doses of systemic baclofen are required to inhibit nociceptive-induced c-fos expression. The paradoxical facilitation of c-fos expression by midazolam in monoarthritic animals, may be due to the reported increase in spinal GABA levels found in those animals.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 14
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

"Hotheaded": The role OF TRPV1 in brain functions (2014)
Another Publication in an International Scientific Journal
Martins, D; Isaura Tavares; Morgado, C
Noradrenaline increases pain facilitation from the brain during inflammatory pain (2013)
Article in International Scientific Journal
Maria Isabel Martins; de Vries, MG; Teixeira-Pinto A; Fadel, J; Wilson, SP; Westerink, BHC; Isaura Tavares
N-acyldopamines control striatal input terminals via novel ligand-gated cation channels (2009)
Article in International Scientific Journal
Ferreira, SG; Lomaglio, T; António Avelino Silva; Francisco Cruz; Oliveira, CR; Cunha, RA; Kofalvi, A

See all (11)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-13 at 10:09:27 | Privacy Policy | Personal Data Protection Policy | Whistleblowing